Beth Fand Incollingo

Tecentriq is approved as an initial treatment for non-small cell lung cancer that has spread and expresses the protein PD-L1 but does not have alterations in the EGFR or ALK genes.

The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors.

Velcade not only delays the progression of mantle cell lymphoma when given after stem cell transplant but also prolongs survival. However, the treatment comes with significant side effects.

The PARP inhibitor Rubraca represents a new treatment option for men with metastatic castration-resistant prostate cancer that expresses a BRCA gene mutation and has been previously treated with hormonal therapy and taxane-based chemotherapy.

The Affordable Care Act allowed states to extend Medicaid coverage to more residents with low incomes or disabilities. Cancer death rates took a bigger dive in the states that utilized this provision, a nationwide study found.

Most people are in the dark about Lynch syndrome, a condition that predisposes individuals to cancer. Patient advocacy group AliveAndKickn works to illuminate the issue.

Lynparza and Avastin are now approved for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin.

Screening for lung cancer saves lives, but many aren’t aware it’s an option. Here’s what people who face a high risk of the disease should know.

Tabrecta (capmatinib) will treat patients with metastatic non-small cell lung cancer that has a mutation leading to MET exon 14 skipping. The drug is the first targeted option for patients with lung cancer and this type of mutation.

The PARP inhibitor Lynparza improves survival and delays disease progression in men with metastatic castration-resistant prostate cancer that expresses certain gene mutations inhibiting DNA repair, a study shows.

An imaging technique known as PSMA PET/CT can detect disease spread at diagnosis more effectively than conventional scans, helping doctors to prescribe appropriate treatments.

Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.

The Food and Drug Administration approved the targeted therapy Tukysa as part of a drug combination to treat HER2-positive breast cancer. Here’s what you need to know.

Based on objective response rate and duration of response measured in a phase 2 study, the Food and Drug Administration approved Trodelvy, an antibody-drug conjugate, for use in previously treated patients with metastatic triple-negative breast cancer.

The Food and Drug Administration approved Tukysa, which is indicated for use with two other drugs after patients have completed treatment with prior therapies targeting the protein HER2.

First validated prognostic score offers valuable insights for patients with chronic lymphocytic leukemia who are prescribed active surveillance.

Using immunotherapy earlier, immediately after the conclusion of chemotherapy to treat metastatic bladder cancer, can delay the time until disease progression.

Patient advocacy group Facing Our Risk of Cancer Empowered addressed individuals with hereditary cancer syndromes to offer suggestions for decreasing anxiety and fear during the COVID-19 pandemic.

Many health systems that treat people with cancer are recommending virtual visits, both for patients who need routine checkups and those who suspect they have the virus known as COVID-19.

The first study to look at cancer prevalence in transgender people and examine the health of transgender cancer survivors also found concerning health trends among transgender women and gender nonconforming people.

Most people are in the dark about Lynch syndrome, a not uncommon condition that predisposes individuals to cancer. Patient advocacy group AliveAndKickn works to illuminate the issue.

The Food and Drug Administration approved Sarclisa, as adding the targeted drug to combination therapy delays the progression of multiple myeloma in previously treated patients.

In deciding when to undergo mastectomy or oophorectomy, women with BRCA gene mutations must weigh the importance of their fertility against their anticipated longevity.

Anyone who wants to enroll in a clinical trial should first weigh all the details. Patients should ask key questions like these before signing up.

From Neil Peart’s passing following a battle with brain cancer to a new online support group for men with testicular cancer, here’s the news making an impact in the cancer landscape.

By taking part in a new survey series, patients with lung cancer can shed light on their quality of life and help drive research.

Even after her death from breast cancer, a pediatric nurse continues to help heal children with a book meant to lift their spirits and raise money for their care.

The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.

Launched in April 2018, the podcast hosted by Eleanor Griffith of Grey Genetics tells the stories of people living with genetic mutations that predispose them to cancer or other diseases.

Doing a few hours of exercise per week can help prevent kidney, liver, endometrial, colon and breast cancers, as well as multiple myeloma and non-Hodgkin lymphoma, a large study found.